Introduction
Down syndrome (trisomy 21) is associated with congenital anomalies in 64% of cases. The cardiac anomalies are commonest, followed by digestive system, musculoskeletal system, urinary system, respiratory and other system anomalies. 1 Estimated worldwide incidence of Down syndrome is 1:1,000-1:1,100, 0.827:1000 in USA 2 and 1.8:1000-1.6:1000 in Egypt. 3 Cholestasis was reported to affect 3.9% of neonates and infants with Down syndrome in a population-based study. 4 The cholestasis in Down syndrome was reported to be due to the probability of a smaller circulating bile acid pool size, a lower rate of synthesis, reduced recirculation of bile acids and immature function of the canalicular bile acid transporting system. 5 The increased susceptibility of cholestasis in Down syndrome was not mapped to chromosome 21, i.e. major genes controlling the uptake, synthesis, or secretion of bile acids in human hepatocytes, synthesis, or ileal enterocytes. 6 The aim of this study was to define the spectrum of clinical presentations, course and outcome of cholestasis in infants with Down syndrome.
Subjects And Methods Subjects
This is an observational study that included a retrospective analysis of data of a cohort of infants with Down syndrome and cholestasis who followed up during 2005-2015 at the Pediatric Hepatology Clinic, New Children Hospital, Cairo University, Egypt. The study was approved by the Pediatric Department Committee for Post-Graduate Studies and Research, and by the Post-Graduate Studies and Research Administration, Faculty of Medicine, Cairo University, Egypt. Parental approval was not applicable to this retrospective, observational, non-interventional cohort study. 7 The study complies with the Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects. 8 
Methods
We revised all files of neonates and infants who presented with cholestasis and clinical features of Down syndrome (trisomy 21) during 2005-2015. We analyzed all data of recruited children, including the history of age at onset of symptoms, age at presentation, presenting symptom, complications and/or associations of liver disease, neurologic disease, age of the patient at the time of the study, weight and height percentiles, and outcome. Anthropometric measures were plotted against Egyptian percentiles for children with Down syndrome weight and height 3 and recorded as percentiles for age.
Etiology of cholestasis was studied according to clinical judgment, i.e., virology, bile acids, metabolic screen, imaging and liver biopsy.
The outcome was graded into resolved, improved, stationary, progressive and death. The resolved outcome was when the cholestasis resolved without sequelae; improved, with an improvement of cholestasis but did not resolve completely; stationary was coined to those who did not improve or deteriorate; while progressive was coined to those where cholestasis increased.
Statistical Analysis
All the statistical analyses in this study were conducted using the Statistical Package for Social Sciences version 19 (SPSS, Chicago, IL). Simple frequency, cross-tabulation, descriptive analysis, tests of significance (t-test for parametric data and χ 2 tests for non-parametric numbers N5), and correlations were employed.
Results
During 2005-2015 only 61 infants with Down syndrome presented to the Pediatric Hepatology Clinic, Cairo University. Six (9.2%) dropped out and did not show up for a second visit; they were all females ( Figure 1 ). The other 55 were followed up for 12.1 ± 16.7 months. Of them, 28 (51%) were females and 27 (49%) males. Mean ± SD age at onset of cholestasis was 1.23 ± 11.78 months, and at presentation to our medical attention was 2.1 ± 9.2 months. Seventeen (30.1%) were the product of a consanguineous marriage. Fifteen (27.3%) had a history of another family member affected by cholestasis. The symptoms, signs of the studied cohort, their serum bilirubin and liver enzymes are shown in Tables 1 and 2, respectively. Liver biopsy was performed in 32 (58.2%) subjects and the findings are shown in Table 2 .
Associated congenital cardiac anomalies were encountered in 14 (25.4%) children (Table 1) . No other anomalies were encountered in our studied cohort. None had any bone marrow-associated disease.
Etiology and outcome of cholestasis in the studied cohort of neonates and infants with down syndrome are shown in Figures 2 and 3 , respectively.
None of the affected infants had EHBA, 37 (67.3%) had neonatal hepatitis and 18 (32.7%) suffered from nonsyndromic paucity of intrahepatic biliary radicals. Cholestasis resolved in 35 (63.6%). None tested positive for viral screening known to cause neonatal hepatitis or metabolic workup and none had progressive familial intrahepatic cholestasis ( Figure 2 ). One child had massive fibrosis, with unidentified underlying pathology, suggesting congenital hepatic fibrosis. Figure 1 depicts the diagnosis and outcome of the studied cohort. They all received fat-soluble vitamin supplements and 29 (52.72%) received UDCA also. Of them, 21 (72.4%) suffered from complications. Both those who received UDCA and those who did not were matched as regards severity of cholestasis (p= 0.17). UDCA use was associated with poorer outcome (p= 0.000) and complications (p= 0.016) ( Table 3) . UDCA in neonates with Down syndrome and cholestasis carried a 3.4-fold risk of poor prognosis (p= 0.001) (95% confidence interval) ( Figure 3 ).
Discussion
During 2005-2015, 7.8% of the neonates and infants who presented with cholestasis to the Pediatric Hepatology Clinic, Faculty of Medicine, Cairo University had the Down syndrome (trisomy 21) phenotype. Clinically, cholestasis was mostly without organomegaly, where only 36.5% and 40% had hepatomegaly and splenomegaly, respectively. The outcome was generally favorable unless UDCA was given.
Congenital Heart Disease Was Encountered In Only 25% Of Cases And None Had Cyanotic Heart Disease
Down syndrome is associated with congenital heart disease (CHD) in 40-60%, [9] [10] [11] with a dramatic increase from about 20% in the early 1970s to more than 50% in the late 1980s (p = 0.0001) in certain areas. 12 In Egypt, studies of the prevalence of CHD in Down syndrome are limited, but the reported range was almost 40%. 13, 14 It is not clear why our cohort had less CHD compared to other populations of Down syndrome. More studies are required to establish or refute a protective effect of placental metabolism of environmental factors that are responsible for the development of CHD in a developing fetus with Down syndrome and/or cholestasis. The sample size is small, however, to draw sound conclusions, yet it remains an observation that CHD is less prevalent among Down syndrome with cholestasis, and the CHD spectrum did not include cyanotic heart disease. 16, 17 which might arrest the inflammatory process of EHBA. 
Paucity Of Intrahepatic Biliary Radicals Has Excellent Prognosis In Down Syndrome
Generally, paucity of intrahepatic biliary radicals has a 69% chance of clearance of cholestasis in absence of UDCA intake, 18 yet 94.4% of our cohort of neonates and infants with Down syndrome with paucity of intrahepatic biliary radicals cleared the cholestasis. Again, it seems that Down syndrome enhances clearance of cholestasis. This effect could be attributed to the compromised immunity in Down syndrome; this compromise will not mount massive destructive effect in the cholestasis inflammatory process. 19 
We Could Not Identify The Etiology Of Neonatal Hepatitis In Down Syndrome
The etiology of cholestasis of all of our studied neonates and infants with Down syndrome was idiopathic hepatitis, despite undergoing the battery of investigations to identify etiology (metabolic, congenital and infectious) when appropriate according to clinical situation. 18 The etiology of neonatal cholestasis in our studied cohort remained idiopathic, with no overlap in etiology. We did not come across any cases of cystic fibrosis, infections, or galactosemia or any other etiology in our cohort with Down syndrome. 
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UDCA Is Not Effective And Is Not Safe In Cholestasis In Down Syndrome
UDCA was found to be ineffective in clearing cholestasis in neonates and infants with Down syndrome, and its use was associated with significantly worse outcome. UDCA compromised the outcome of those with Down and cholestasisonly 44.8% of those who received UDCA resolved the cholestasis, compared to 84.6% of those who did not receive UDCA. UDCA generally impedes resolution of cholestasis in neonatal hepatitis compared to no UDCA (44.8% compared to 70.2%, respectively). 18 The discouraging effect of UDCA is exaggerated in our studied cohort. It is not clear why UDCA is more toxic in neonates with Down syndrome and cholestasis. The UDCA toxicity in cholestasis in Down syndrome might be attributed to their compromised detoxification of medications, e.g., methotrexate, glucocorticoids, anthracyclines, etc. 20 It might be related to trisomy 21 type karyotyping or other genetic makeup that needs further investigation.
Conclusion
Cholestasis complicates Down syndrome. We did not come across EHBA among our studied cohort in 10 years. Down syndrome seems to protect against the development of EHBA. Use of UDCA in cholestasis associated with Down syndrome compromises resolution of cholestasis and its use is associated with poor prognosis. UDCA use in cholestasis associated with Down syndrome should be contraindicated. What Is Known?
1. Exclusion of surgical causes of cholestasis is invasive, yet it is part of workup in every neonate with cholestasis as surgical portoenterostomy should not be delayed beyond 3 months of age to halt the march of biliary cirrhosis. 2. Cholestasis associated with trisomy 21 (Down syndrome) has been reported previously.
What Is New?
1. Cholestasis in Down syndrome was never found to be due to biliary atresia; we did not come across a single obstructive cholestasis in Down syndrome in 10 years of practice. 2. Generally, the outcome of cholestasis is favorable in Down syndrome, especially if the etiology of cholestasis is non-syndromic paucity, unless they receive ursodeoxycholic acid, as its' use is associated with poor outcome, complications and fatality.
